Extending Remission and Reversing New-Onset Type 1 Diabetes by Targeted Ablation of Autoreactive T Cells

Area of Science:

• Immunology
• Endocrinology
• Molecular Biology

Background:

• Type 1 diabetes (T1D) treatment faces challenges in preserving endogenous insulin production and protective immunity.
• Broad immunosuppression for T1D has limited success and compromises beneficial immune responses.

Purpose of the Study:

• To develop a novel therapeutic strategy for T1D that specifically depletes diabetogenic T cells while preserving insulin production and protective immunity.
• To explore the potential of targeting p53 and cell cycle checkpoints for T1D treatment.

Main Methods:

• Utilized small molecular inhibitors to potentiate p53 and inhibit the G2/M cell cycle checkpoint.
• Administered inhibitors at the onset of disease in a model of T1D.
• Assessed the impact on diabetogenic effector T (Teff) cells, insulin production, islet function, and other T cell populations.

Main Results:

• Inhibitors effectively drove apoptosis of activated T cells in vivo.
• Treatment significantly reduced diabetogenic Teff cells, prolonged disease remission, and preserved functional islets.
• Naive, memory, and regulatory T cell populations remained functionally intact.

Conclusions:

• Targeted manipulation of p53 and cell cycle checkpoints offers a new therapeutic approach for preserving islet beta-cells in new-onset T1D.
• This strategy holds promise for protecting islet allografts and maintaining endogenous insulin production post-transplant.